Clinical Trials
3 trialsNCT04795869 2023-10-10
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Withdrawn
NCT02533700 2020-03-10
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Shandong Provincial Hospital
Phase 2 Unknown
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated